KINISA JPMorgan_JPM25_Slides for Upload_10.13.25_1030am.pdf

1、AnnaLiving with Recurrent PericarditisWere relentless and focused on putting patients at the center of everything we do as we strive to develop life-changing medicinesWho We AreJP Morgan ConferenceJANUARY 20252This presentation(together with any other statements or information that we may make in co

2、nnection herewith)contains forward-looking statements with respect to Kiniksa Pharmaceuticals International,plc(and its consolidated subsidiaries,collectively,unless context otherwise requires,“Kiniksa,”“we,”“us”or“our”).In some cases,you can identify forward looking statements by terms such as“may,

3、”“will,”“should,”“expect,”“plan,”“anticipate,”“could,”“intend,”“goal,”“design,”“target,”“project,”“contemplate,”“believe,”“estimate,”“predict,”“potential,”“strategy,”or“continue”or the negative of these terms or other similar expressions,although not all forward-looking statements contain these iden

4、tifying words.All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements,including without limitation,statements regarding our strategy;potential value drivers;potential indications;potential product candidates;poten

5、tial market opportunities and competitive position;ongoing,planned and potential clinical trials and other studies;timing and potential impact of clinical data;regulatory and other submissions,applications and approvals;commercial strategy and commercial activities;expected run rate for our cash,cas

6、h equivalents and short-term investments;expected funding of our operating plan;financial guidance;and capital allocation.These statements involve known and unknown risks,uncertainties,and other important factors that may cause our actual results,performance or achievements to be materially differen